Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation
Werte in diesem Artikel
SAN DIEGO, April 23, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA).
Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of those NASDAQ: NTLA shares also have certain options and contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On February 11, 2025, a NASDAQ: NTLA investor filed a lawsuit against Intellia Therapeutics, Inc. over alleged violations of securities laws. The plaintiff alleged that between July 30, 2024 and January 08, 2025, the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that they possessed reliable information pertaining to the viability of NTLA-3001's development and eventual marketing, if approved, that Intellia's optimistic reports of timelines, including dosing and future studies of the drug, fell short of reality; the NTLA program was not viable or sustainable for Intellia because viral-based editing programs remained expensive and inefficient in comparison to then-existing non-viral delivery methods, that Intellia was not equipped to timely dose patients with NTLA-3001, maintain the drug's research and development, or even to maintain its full staff in light of the existing scientific landscape surrounding viral-based editing drugs, and that even if NTLA-3001 proved successful, the use of viral-based editing drugs is costly, inefficient, and poor mitigators of adverse effects in patients.
Those who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lawsuit-for-investors-in-shares-of-intellia-therapeutics-inc-nasdaq-ntla-announced-by-the-shareholders-foundation-302435434.html
SOURCE Shareholders Foundation, Inc.
Ausgewählte Hebelprodukte auf Intellia Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Intellia Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Intellia Therapeutics Aktie News
Intellia Therapeutics Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Intellia Therapeutics nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 02.11.18 | Intellia Therapeutics Neutral | Wedbush Morgan Securities Inc. | |
| 15.05.18 | Intellia Therapeutics Buy | Chardan Capital Markets | |
| 28.03.17 | Intellia Therapeutics Buy | Chardan Capital Markets | |
| 31.05.16 | Intellia Therapeutics Outperform | Wedbush Morgan Securities Inc. |
